Pasithea Therapeutics’ Post

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

Lykos Therapeutics Launches With $100 Million For MDMA Treatments The Multidisciplinary Association for Psychedelic Studies (MAPS) has officially launched Lykos Therapeutics (formerly MAPS PBC) as a for profit biotechnology company to advance MDMA assisted therapies. For decades, MAPS has been leading the psychedelic renaissance through their scientific research and advocacy efforts. The pivotal launch of Lykos marks a potential turning point in the future of commercializing MDMA assisted therapies. What's happening, why it matters, and more: https://lnkd.in/e-xZiDMM Featured | cc: Rick Doblin, Michael Mullette, William Stewart, Brom Rector, CFA, Henry Elkus, Colin Whelan, Matt Saunders, Kevin Yorn #psychedelics #biotech

The anti-aging therapeutics market is expected to grow at a 16.53% CAGR through 2030… And a major market player in this space, according to Insight Analytics? CytoMed Therapeutics (NASDAQ: GDTC) Read the full market report at: https://shorturl.at/7xxFA #CarTcells #cartcelltherapy #cancertherapy #biotechstocks #biotech #undervalued #immunotherapy #nasdaq #nasdaqstocks #preclinical #undervaluedstocks #antiaging #investing

Would you like to know more about the science behind drugging biomolecular condensates?   Check out this video to see how Dewpoint leverages the unique properties of condensates to expand the druggable proteome with condensate-modulating therapeutics (c-mods).    For a deeper dive into c-mods and the approaches for drugging condensates, read our recently published perspective in Nature Reviews Drug Discovery: https://lnkd.in/e8u6CkDs Learn more about Dewpoint here: https://lnkd.in/dZHWWmA8

Examining the clinical use of engineered exosomes for therapeutic protein delivery: in this concise review, Chulhee Choi at ILIAS Biologics Inc. and collaborators discussed the challenges in developing exosomes as drug carriers and provided insights into strategies for their effective clinical translation https://lnkd.in/gTmHpiDe Additionally, they highlighted preclinical studies that have successfully used anti-inflammatory exosomes and suggested future directions for exosome therapeutics. An article also authored by Minseong Kim, Hojun Choi, Deok-Jin Jang, Hye-Jung Kim, Yujin Sub and Heon Yung Gee #extracellularvesicles #exosomes #bioengineering #drugdelivery #therapeutics #Vesiculab

Exosome research market Worth $356 million by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://lnkd.in/d7xn3yke The global exosome research market in terms of revenue was estimated to be worth $169 million in 2023 and is poised to reach $356 million by 2028, growing at a CAGR of 16.0% from 2023 to 2028. Thermo Fisher Scientific Bio-Techne System Biosciences QIAGEN Danaher Corporation Diagenode, a Hologic company Hitachi Chemical FUJIFILM Holdings America Corporation Lonza JSR Corporation Miltenyi Biotec Illumina Takara Bio USA, Inc. Malvern Instruments GmbH abcam Evox Therapeutics Ltd Capricor Therapeutics, Inc. Aegle Therapeutics Coya Therapeutics, Inc. Nano24 ReNeuron Group Plc Anjarium Biosciences ArunA Biomedical Carmine Therapeutics Ciloa SAS Creative Biolabs Direct Biologics EXOCAN HEALTHCARE TECHNOLOGIES ExoCoBio ExonanoRNA Exopharm Ltd Exosome Diagnostics ILIAS Biologics Inc. XOStem, Inc VivaZome Therapeutics Organicell Regenerative Medicine OmniSpirant Limited NOVADIP Biosciences S.A.

CS Sheffield, widely known as Sheff from Sheff Station, joins us on April 3rd at 12pm ET to discuss what he looks for when analyzing biotech companies, catalysts, and to discuss the current biotech landscape. CS was a former executive at Merck and Pfizer for a combined 27 years in their oncology division and has been investing in biotech for 18 years. We are very much looking forward to the discussion! Please register via the link below: https://lnkd.in/dhZYMDVN #webinar #biotech #tradingbiotech #biotechinvesting #pharma #betherewhenithappens #catalysts

Interested in learning about #flowcytometry? Watch our webinar on-demand to learn about the capabilities of this advanced technology.

FibroBiologics is set to join the Russell 2000® Index effective July 1, 2024, according to a preliminary list of additions. This milestone reflects our growth and commitment to developing novel therapeutics using fibroblasts. Joining the #Russell2000 marks a significant step in increasing our visibility in the investment community and enhancing shareholder value. For more: https://bit.ly/4cHC6ST #Biotechnology #InvestmentGrowth